MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
3.240
+0.040
+1.25%
After Hours: 3.280 +0.04 +1.23% 18:53 06/21 EDT
OPEN
3.250
PREV CLOSE
3.200
HIGH
3.290
LOW
3.165
VOLUME
1.96M
TURNOVER
0
52 WEEK HIGH
9.08
52 WEEK LOW
2.280
MARKET CAP
477.47M
P/E (TTM)
-2.1836
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADPT last week (0610-0614)?
Weekly Report · 4d ago
Adaptive Biotechnologies Insiders Sell US$664k Of Stock, Possibly Signalling Caution
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insiders have sold shares in the last year. The biggest single sale by an insider was US$167k to the Co-Founder of the company, Chad Robins, for US$3.44 per share. In the last 12 months the company has had no insider purchases of shares. But the company does have a high level of insider ownership. You can see the insider transactions of Adaptive BiOTEchnologies over the past year.
Simply Wall St · 06/13 10:06
Weekly Report: what happened at ADPT last week (0603-0607)?
Weekly Report · 06/10 09:24
Wednesday's ETF Movers: ARKG, IYM
NASDAQ · 06/05 16:03
Weekly Report: what happened at ADPT last week (0527-0531)?
Weekly Report · 06/03 09:25
Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Benzinga · 05/31 11:35
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies Corporation's clonoSEQ test for measurable residual disease assessment will be included in several oral and poster presentations. The company aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. The company's next-generation sequencing-based test will be featured at several conferences.
Barchart · 05/31 06:30
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2024 Update
Seeking Alpha · 05/30 00:54
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.